Shots: The approval is based on P-III head-to-head PEGASUS study assessing Empaveli vs Soliris (eculizumab) in 80 adults with PNH. Participants should be Soliris stable for at least 3mos. with […]readmore
Tags : Soliris
Regulatory
Alexion’s Soliris (eculizumab) Receives European Commission’s Approval for Neuromyelitis Optica
Shots: The EC approval is based on P-III PREVENT study assessing Soliris vs PBO in patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of therapy and […]readmore
Biotech
Regulatory
Alexion’s Soliris (eculizumab) Receives FDA’s Approval for Anti-Aquaporin-4 Antibody Positive
Shots: The approval is based on P-III PREVENT study results assessing Soliris vs PBO in patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive The P-III […]readmore